Heart Failure

Frontiers in Cardiology
Herausgegeben:Kitabatake, A.; Sasayama, S.; Francis, G.S.

• Broschiertes Buch

Produktbeschreibung

Remarkable progress has been made in understanding and treating heart failure. Among other developments, angiotensin-converting enzyme inhibitors and b blockers have been found to have beneficial therapeutic effects, reinforcing the view that heart failure may be both a hemodynamic and a neurohumoral disorder. The Japanese Heart Failure Society was established to curb the threat of heart failure through research, education, and clinical practice. At the Societys 2nd Annual Scientific Meeting in Sapporo, molecular biologists, physiologists, clinicians, surgeons, and researchers in related fields met to strengthen professional bonds for the ultimate goal of preventing death from heart failure. This book contains presentations from the Sapporo conference that provide new insights into heart failure in the areas of pathophysiology, cardiac sudden death, medical and surgical treatment, and promising new gene therapy.

Produktdetails

• Verlag: Springer / Springer Japan / Springer, Berlin
• Artikelnr. des Verlages: 978-4-431-68333-9
• Softcover reprint of the original 1st ed. 2000
• Seitenzahl: 276
• Erscheinungstermin: 24. Februar 2012
• Englisch
• Abmessung: 235mm x 155mm x 16mm
• Gewicht: 423g
• ISBN-13: 9784431683339
• ISBN-10: 443168333X
• Artikelnr.: 36122684

Inhaltsangabe

Part 1 New Insights in Pathophysiology of Heart Failure: Neurohormones in Advanced Heart Failure. Recent Progress in the Natriuretic Hormone Research. Cytokines and Heart Failure: Pathophysiological Roles. Endothelial Dysfunction in Heart Failure. Apoptosis: Its Mechanism and Meaning in Heart Failure. Mechanisms of Cardioprotection with Ischemic Preconditioning. Role of NO in Myocardial Injury Induced by Oxidative Stress. Cardiac Remodeling: Role of Neovascularization in Heart Failure.- Part 2 Heart Failure and Cardiac Sudden Death: QT Prolongation Syndrome in CHF. ICD Therapy: Can they prevent sudden death in CHF patients? Arrhythmias in CHF: To treat or not to treat.- Part 3 Medical Treatment of Heart Failure: Beyond ACE Inhibitors: New Concepts of Clinical Practice Guideline For Heart Failure. AII Antagonism in Heart Failure: Evaluation of Losartan in the Elderly Trial. Beta-Blockers: Benefits and Risks from Beta-blockade Therapy. Future Prospects of Endothelin Antagonists in Heart Failure. Heart Failure: Potential Benefit of Growth Hormone Therapy. Adenosine and Cardioprotection: Its Implication in Heart Failure.- Part 4 Gene Therapy for Heart Failure: Current Status and Future Prospect: In vivo Gene Supplementation for the Therapy of Cadiomyopathy. Lessons From Beta2 Receptor Transgenic Mouse. In vivo transfection of cis element 'decoy' against NF-kappaB binding site prevents myocardial damage. Scar Tissues to Viable Myocytes.- Part 5 Surgical Treatment for Heart Failure: A New Paradigm beyond Cardiac Transplantation Treatment of Profound Heart Failure by Ventricular Assist System. Ventriculoplasty of the End-Stage Heart Failure 'Batista' operation and 'Dor' operation.